Oncology News

Oncology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Yang ES et al. - Targeted biologic therapies such as the monoclonal antibody Cetuximab has demonstrated efficacy with radiation that appear comparable to chemoradiation combinations and has a favorable toxicity profile. This review will discuss key clinical trials supporting the current standard of care. Emerging new technologies such as intensity modulated radiation therapy (IMRT) and image-guided radiation therapy (IGRT) will also be reviewed.

Related Articles

Cessation of alcohol drinking, tobacco smoking and the reversal of head and neck cancer risk
International Journal of Epidemiology, 10/08/09    Relevance Score: 84%

Planned neck dissection following primary chemoradiation for advanced-stage head and neck cancer
Otolaryngology Head and Neck Surgery, 10/13/09    Relevance Score: 83%

Extracts from The Cochrane Library: Erythropoietin as an adjuvant treatment with (chemo) radiation therapy for head and neck cancer
Otolaryngology Head and Neck Surgery, 10/12/09    Relevance Score: 83%

Clinical Features and Short-Term Outcome of Critically Ill Patients With Head and Neck Cancer in the Medical Intensive Care Unit
American Journal of Clinical Oncology, 10/07/09    Relevance Score: 83%

Sheddase Activity of Tumor Necrosis Factor-alpha Converting Enzyme Is Increased and Prognostically Valuable in Head and Neck Cancer
Cancer Epidemiology, Biomarkers & Prevention, 10/27/09    Relevance Score: 82%


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address